Chronic obstructive pulmonary disease (COPD)
610 results
401 - 500
Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease- Non‐invasive ventilation during exercise training for people with chronic obstructive pulmonary disease
- Smoking cessation for people with chronic obstructive pulmonary disease
- Airway clearance techniques for chronic obstructive pulmonary disease
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Uncertain benefit of home noninvasive positive pressure ventilation for adults with chronic obstructive pulmonary disease- Telerehabilitation for chronic respiratory disease
Action plans for chronic obstructive pulmonary disease - Pulmonary function tests
- Telehealthcare for chronic obstructive pulmonary disease
- Nutritional supplementation for stable chronic obstructive pulmonary disease: Cochrane systematic review
- Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
- Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Oral theophylline for chronic obstructive pulmonary disease
- Beclometasone for chronic obstructive pulmonary disease: Cochrane systematic review
- Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease
- Canadian Thoracic Society guidelines for pharmacotherapy of stable chronic obstructive pulmonary disease
- Ipratropium bromide versus short acting beta‐2 agonists for stable chronic obstructive pulmonary disease
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
- Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis: Cochrane systematic review
- Dyspnoea
- Short‐acting beta2‐agonists for stable chronic obstructive pulmonary disease
- Tiotropium, inhaled steroids and long-acting beta2-agonists alone or in combinations for chronic obstructive pulmonary disease
- Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease
- Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
- Oxygen therapy during exercise training in chronic obstructive pulmonary disease
- Guidelines for the management of COPD
- Nocturnal positive pressure ventilation for COPD
- Aclidinium bromide for stable chronic obstructive pulmonary disease
- Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest
- Optimal intensity and type of leg exercise training for people with chronic obstructive pulmonary disease
- Long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review
- Self‐management interventions for people with chronic obstructive pulmonary disease
- Chronic heart failure
- Inhaled short‐acting beta2‐agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
- Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease
- Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care
- Inhaled corticosteroids and risk of fractures
- Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
- Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease: Cochrane systematic review
- Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long‐term condition: a mixed methods review
- Long-acting bronchodilators similarly safe in COPD patients
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
- Oral theophylline for chronic obstructive pulmonary disease
- Tiotropium versus placebo for chronic obstructive pulmonary disease
- Water-based exercise training for chronic obstructive pulmonary disease
- Water-based exercise training for chronic obstructive pulmonary disease: Cochrane systematic review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
- Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease: Cochrane systematic review
- Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease
- Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease
- Hospital at home for acute exacerbations of chronic obstructive pulmonary disease
- Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease
- Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
- Vitamin D for the management of chronic obstructive pulmonary disease
- Statins versus placebo for people with chronic obstructive pulmonary disease: Cochrane systematic review
- Anticholinergic bronchodilators versus beta2‐sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
- Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
- In high-risk patients with chronic obstructive pulmonary disease, dupilumab slightly reduces moderate exacerbation (BOREAS)
- Oxygen therapy in the pre‐hospital setting for acute exacerbations of chronic obstructive pulmonary disease
- Cardioselective beta‐blockers for reversible airway disease
- Long-acting beta2-agonist in addition to tiotropium versus either agent alone for chronic obstructive pulmonary disease
- Pressurised metered‐dose inhalers versus all other hand‐held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease
- Self-management for patients with chronic obstructive pulmonary disease
- Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease
- Heliox for treatment of exacerbations of chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
- Pulmonary rehabilitation for chronic obstructive pulmonary disease
- Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease
- Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
- Short‐term ambulatory oxygen for chronic obstructive pulmonary disease
- Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review
- Integrated disease management interventions for patients with chronic obstructive pulmonary disease
- Digital interventions for the management of chronic obstructive pulmonary disease
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
- LABA+LAMA+ICS associated with greater decline in all-cause mortality than LABA+LAMA in patients with severe COPD (IMPACT)
- Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease: Cochrane systematic review